Li Ming-Xing, Li Long-Fei, Zhang Lin, Xiao Zan-Gang, Shen Jing, Hu Wei, Zeng Qiang, Cho Chi-Hin
Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan Province. China.
School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. China.
Curr Med Chem. 2017;24(9):918-927. doi: 10.2174/0929867324666170214110633.
Vitamin D has been widely used as a dietary supplement for the prevention and treatment of bone disorders. Epidemiological and preclinical studies demonstrated the anticancer action of vitamin D in a variety of cancers including those in the gastrointestinal (GI) tract. In these studies the inhibitory action of vitamin D on cancer stem cells (CSCs) has been a focus and is also an important subject to revolutionize the therapeutic potential of vitamin D on cancer treatment. Here, we summarize the involvement of CSC markers and factors and also their signaling pathways in the development of cancers in the esophagus, stomach, colon, pancreas and also liver. It is also evidenced that vitamin D could inhibit these markers and factors and their related signaling pathways to suppress tumor progression. All these information could provide new strategies in repurposing vitamin D as therapeutic agent to inhibit cancers in the GI tract.
维生素D已被广泛用作预防和治疗骨骼疾病的膳食补充剂。流行病学和临床前研究表明，维生素D在包括胃肠道（GI）癌在内的多种癌症中具有抗癌作用。在这些研究中，维生素D对癌症干细胞（CSC）的抑制作用一直是焦点，也是彻底改变维生素D在癌症治疗中治疗潜力的重要课题。在这里，我们总结了CSC标志物、因子及其信号通路在食管癌、胃癌、结肠癌、胰腺癌以及肝癌发生发展中的作用。也有证据表明，维生素D可以抑制这些标志物、因子及其相关信号通路，从而抑制肿瘤进展。所有这些信息可为将维生素D重新用作治疗剂以抑制胃肠道癌症提供新策略。
